Drugs / M28z1XXPD1DNR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04577326 | Sep 2020 → Sep 2026 overdue | malignant pleural mesothelioma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-12-09 | Atara Biotherapeutics | Results Atara Biotherapeutics Announces Preliminary Results for ATA2271, a Next-Generation Autologous Mesothelin-targeted CAR T-cell Therapy for Solid Tumors, at ESMO Immuno-Oncology Congress 2021 atarabio.com ↗
Importantly, ATA2271 CAR T-cells persisted in patients’ peripheral blood for greater than four weeks and was associated with upregulated effector cytokines. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-12-09 | Atara Biotherapeutics | Atara Biotherapeutics Announces Preliminary Results for ATA2271, a Next-Generation Autologous Mesothelin-targeted CAR T-cell Therapy for Solid Tumors, at ESMO Immuno-Oncology Congress 2021 atarabio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M28z1XXPD1DNR | “A single dose of M28z1XXPD1DNR CAR T cells will be instilled into the pleural cavity via a pleural catheter or through an interventional radiology-guided needle.” NCT04577326 ↗ |
| Route | Other | “M28z1XXPD1DNR CAR T cells will be instilled into the pleural cavity” NCT04577326 ↗ |